Table of Contents
Licensing
| Hanmi Partners RAF inhibitor HM95573 with Genentech in a deal worth US$910 M | Abstract pdf html |
| Jawala Prasad |
| Teva Tries its Luck with Risky NGF Inhibitor Class by Partnering with Regeneron | Abstract pdf html |
| Jawala Prasad |
| Amgen Bolsters its CV Pipeline with Arrowhead’s RNA Interference Therapies | Abstract pdf html |
| Jasmine Kalsi |
| AstraZeneca Streamlines Portfolio with Four More Externalisation Deals | Abstract pdf html |
| Keshav Mahawar |
This work is licensed under a Creative Commons Attribution 3.0 License.